Welcome to our dedicated page for Livanova Plc news (Ticker: LIVN), a resource for investors and traders seeking the latest updates and insights on Livanova Plc stock.
LivaNova PLC (NASDAQ: LIVN) is a global medical technology company headquartered in London, focused on select neurological and cardiac conditions. This news page aggregates company announcements, clinical updates, investor communications, and other disclosures that LivaNova issues through press releases and related channels.
Readers can find coverage of LivaNova’s neuromodulation activities, including developments in VNS Therapy for Drug‑Resistant Epilepsy and results from the CORE‑VNS real‑world study. News items also describe health economics analyses, reimbursement decisions affecting VNS Therapy procedures under U.S. Medicare programs, and scientific presentations at major epilepsy meetings.
The feed also includes updates on LivaNova’s cardiopulmonary business and its heart‑lung support technologies, as well as information on its work in obstructive sleep apnea through proximal hypoglossal nerve stimulation and the aura6000 investigational system. Articles may highlight data from randomized controlled trials, long‑term follow‑up analyses, and presentations at specialized surgical sleep and medical conferences.
In addition, investors can follow LivaNova’s participation in healthcare investment conferences, Investor Day events, and quarterly financial result announcements, which the company often distributes via press release and webcasts. By reviewing this page, users can track how LivaNova communicates about its core Epilepsy and Cardiopulmonary businesses, its research programs, and its long‑range strategic plans.
For anyone researching LIVN stock or monitoring developments in medical technology for neurological and cardiac conditions, this news page offers a centralized view of LivaNova’s public announcements over time.
LivaNova PLC (NASDAQ:LIVN) will hold a conference call on February 24, 2021, at 1 p.m. London time (8 a.m. EST) to discuss its fourth quarter and full-year 2020 results, which will be released prior to the call. Interested parties can access a live audiocast on LivaNova's Investor Relations website. For phone access, dial 844-239-5285 or 512-961-6524, using conference ID 1290829. A replay will be available for 90 days post-call. LivaNova is a global medical technology company dedicated to innovative healthcare solutions, serving over 100 countries.
LivaNova PLC (NASDAQ:LIVN) will host a virtual symposium titled "Updates and Advances in Neuromodulation" at AES2020 on December 6, 2020, from 6 to 8:30 p.m. ET. The event will feature leading clinicians discussing the role of VNS Therapy in treating drug-resistant epilepsy (DRE) and other disorders. Attendees will explore the economic and healthcare burdens of DRE and learn how VNS Therapy can alleviate these challenges. The symposium is free for AES2020 registrants, and a recording will be available afterward.
LivaNova PLC (NASDAQ:LIVN) has announced a strategic divestiture of its heart valve (HV) business to Gyrus Capital for an enterprise value of €60 million (US$73 million). The deal, unanimously approved by LivaNova's Board of Directors, aims to enhance focus on neuromodulation and cardiovascular platforms. The transaction is expected to be dilutive to earnings per share by approximately 10-15 cents in 2021 and may trigger a non-cash impairment charge of US$200 million to US$225 million. Completion is targeted for the first half of 2021, pending regulatory approvals.
LivaNova PLC (NASDAQ:LIVN) announced that CEO Damien McDonald will speak at the Berenberg European Conference 2020 on December 2 at 4 p.m. GMT. Attendees should log in 10 minutes early to prepare for the audiocast. A replay will be available on LivaNova's website within 24 hours for 90 days. Established nearly 50 years ago, LivaNova is a leading global medical technology company focused on innovative solutions for patients’ heart and brain health, employing around 4,000 people across more than 100 countries.
LivaNova PLC (NASDAQ:LIVN) announced that CEO Damien McDonald will engage in discussions at the Piper Sandler 32nd Annual Virtual Healthcare Conference from November 30 to December 3. A pre-recorded discussion will be available on November 23 at 10 a.m. Eastern via LivaNova's Investor Relations webpage. The recording will remain accessible for 90 days, and conference meetings by invitation will occur on December 3. LivaNova, a leading medical technology company headquartered in London, has over 4,000 employees and serves more than 100 countries.
LivaNova PLC (NASDAQ:LIVN) announced that CEO Damien McDonald will present at the Stifel 2020 Virtual Healthcare Conference on November 17 at 10:40 a.m. ET. The live discussion will be accessible via a webcast on the company's Investors section of their website. A replay will be available for 90 days following the event. LivaNova, headquartered in London, focuses on innovative medical technologies across two business sectors: Cardiovascular and Neuromodulation, serving over 100 countries worldwide.
LivaNova PLC (NASDAQ: LIVN) reported third-quarter 2020 results with worldwide sales of $240.1 million, a decline of 10.6% year-over-year. Adjusted diluted earnings per share were $0.38, down from $0.84 in the same quarter last year. The company faced revenue decline due to COVID-19, particularly affecting Cardiopulmonary and Neuromodulation segments. However, Advanced Circulatory Support saw a significant increase of 91.9%. LivaNova's guidance expects a full-year net sales decline of 7-17% on a constant-currency basis.
LivaNova PLC (NASDAQ:LIVN) has acknowledged a letter from PrimeStone Capital LLP, expressing openness to constructive dialogue aimed at enhancing shareholder value. The Company’s leadership has engaged in discussions with PrimeStone over the last few months, reaffirming its commitment to executing its strategic plan and improving patient outcomes through innovative medical technologies. An update on Company performance is scheduled for the third quarter earnings call on October 29, 2020.
LivaNova PLC (NASDAQ:LIVN) announced promising results from the PERSIST-AVR and SURE-AVR studies at the 34th Annual Meeting of the EACTS. The PERSIST-AVR study, involving 910 patients, demonstrated that the Perceval sutureless valve, when used in minimally invasive cardiac surgery, resulted in significantly lower major adverse cardiovascular events (5.2% vs. 10.8% for stented valves) and reduced stroke rates (1% vs. 5.4%). Additionally, SURE-AVR results showed comparable performance between Perceval via minimally invasive techniques and traditional approaches. These findings bolster the case for Perceval's role in innovative heart valve solutions.
LivaNova PLC (NASDAQ:LIVN) will host a conference call on October 29, 2020, at 12 p.m. London time to discuss its third-quarter 2020 results, releasing the results prior to the call. The audiocast will be available in the Investor Relations section of LivaNova's website, with listeners advised to log on 10 minutes early. For telephone participation, dial 844-239-5285 (U.S.) or 512-961-6524 (international), using conference ID 1897870. A replay will be accessible for 90 days post-call. LivaNova operates in Cardiovascular and Neuromodulation sectors, serving over 100 countries.
FAQ
What is the current stock price of Livanova Plc (LIVN)?
What is the market cap of Livanova Plc (LIVN)?
